Inhibition of bradykinin- and thapsigargin-induced Ca2+ entry by tyrosine kinase inhibitors.
We examined the involvement of tyrosine kinase activity in the bradykinin (BK)-mediated signal transduction process. Immunoblots with anti-phosphotyrosine antibodies following BK stimulation of human fibroblasts showed tyrosine phosphorylation of specific proteins that could be inhibited by the tyrosine kinase inhibitors genistein and tyrphostin. Image analysis data from individual cells stimulated by BK in the presence of genistein and tyrphostin showed that these inhibitors block the plateau phase but not the rapid transient phase of the BK-induced calcium response. That the loss of the plateau phase was due to blockage of calcium entry rather than stimulation of calcium pump activity was confirmed by examining the influx of Ba2+ following BK stimulation. The Ca2+ imaging results were confirmed by 45Ca2+ uptake measurements and extended to another tyrosine kinase inhibitor (methyl 2,5-dihydroxycinnamate), which was found to interfere with the fura-2 signal and therefore could not be used in imaging experiments. The fact that three structurally distinct inhibitors of tyrosine kinase activity inhibited BK-stimulated calcium influx, while an inactive analogue of genistein (daidzein) did not, strongly suggests the involvement of tyrosine kinases in the regulation of a BK-induced calcium entry pathway. To our knowledge, this is the first report of tyrosine kinase involvement in the regulation of calcium entry following activation of a receptor that lacks endogenous tyrosine kinase activity and is known to be coupled to phosphatidylinositol turnover. We found that calcium entry in HSWP (human foreskin fibroblast) cells can also be stimulated by emptying the intracellular calcium stores with thapsigargin. Genistein also inhibits the plateau phase of the thapsigargin-induced calcium response while leaving the transient phase intact. This suggests that the Ca2+ influx pathway induced by depletion of intracellular calcium stores with thapsigargin also may be regulated via a tyrosine kinase pathway.
Lee
K M
KM
Department of Pharmacological and Physiological Sciences, University of Chicago, Illinois 60637.
Toscas
K
K
Villereal
M L
ML
D001464:Barium / Q000378:metabolism; D001920:Bradykinin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism*; D000252:Calcium-Transporting ATPases / Q000037:antagonists & inhibitors*; D002396:Catechols / Q000494:pharmacology; D002478:Cells, Cultured; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D016257:Fura-2; D019833:Genistein; D006801:Humans; D015151:Immunoblotting; D007529:Isoflavones / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D009570:Nitriles / Q000494:pharmacology; D019000:Phosphotyrosine; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D012867:Skin / Q000378:metabolism; D013729:Terpenes / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D019284:Thapsigargin; D014443:Tyrosine / Q000031:analogs & derivatives / Q000032:analysis; D020032:Tyrphostins
D002396:Catechols; D007529:Isoflavones; D009570:Nitriles; D013729:Terpenes; D020032:Tyrphostins; C060152:tyrphostin 47; D019000:Phosphotyrosine; D001464:Barium; D014443:Tyrosine; C004742:daidzein; D019284:Thapsigargin; D019833:Genistein; D011505:Protein-Tyrosine Kinases; D000252:Calcium-Transporting ATPases; D001920:Bradykinin; D002118:Calcium; D016257:Fura-2